Article
Eyetech Pharmaceuticals Inc. and Pfizer Inc. have filed a new drug application with the FDA for the 0.3 mg dose of pegaptanib sodium injection (Macugen) as a treatment for AMD (also see Page 46 in this issue).
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.